Rhythm Pharmaceuticals Terminates License and Share Purchase Agreements with RareStone

Boston, MA – March 20, 2025 – Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced it has terminated its Exclusive License and Share Purchase Agreements with RareStone Group Ltd. and RareStone Medicine (Shenzhen) Co., Ltd. Under the termination deal, Rhythm will repay $6.3 million to RareStone and return all previously acquired shares at no additional cost. All rights and obligations under the original agreements are fully discharged, and both parties have mutually released each other from any future claims.